Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: A report from the PEP-CHF study

European Journal of Heart Failure

Volumn 14, Issue 5, 2012, Pages 487-494

  Cleland, John G F ^a   Taylor, Jacqueline ^a   Freemantle, Nick ^a   Goode, Kevin M ^a   Rigby, Alan S ^a   Tendera, Michal ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Diagnosis; Diastolic heart failure; Natriuretic peptide; Preserved ejection fraction

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; LOOP DIURETIC AGENT; NITRATE; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE SIZE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; STROKE VOLUME; SURVIVAL ANALYSIS;

EID: 84860376941     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs049     Document Type: Article

References (32)

1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-1552.
2. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival trial (CONSENSUS). Am J Cardiol 1988;62(suppl A):60A-66A.
3. Marantz PR, Alderman M, Tobin JN. Diagnostic heterogeneity in clinical trials for congestive heart failure. Ann Intern Med 1988;109:55-61.
4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325: 293-302.
5. The SOLVD Investigators. Effect on enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
6. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000;321: 215-218.
7. Ingle L, Cleland JGF, Clark AL. Perception of symptoms is out of proportion to cardiac pathology in patients with 'diastolic heart failure'. Heart 2008;94:748-753.
8. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
9. Nikitin NP, Witte KKA, Clark AL, Cleland JGT. Color tissue Doppler-derived long-axis left ventricular function in heart failure with preserved global systolic function. Am J Cardiol 2003;90:1174-1177.
10. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
11. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-269.
12. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:771-781.
13. Carson P, Massie BM, McKelvie R, McMurray J, Komajda M, Zile M, Ptaszynska A, Frangin G; for the I-PRESERVE Investigators. The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial: rationale and design. J Card Fail 2005;11:576-585.
14. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345.
15. Cleland JGF, Kubanek M, Goode K. Prognostic significance of NTproBNP in patients with a clinical diagnosis of heart failure with a preserved left ventricular systolic function. Eur Cardiovasc Dis 2007;1:41-42.
16. Cleland JGF, Tendera M, Taylor J. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007;357:829-830.
17. Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol 2008;102:733-737.
18. McKelvie RS, Komajda M, McMurray J, Zile M, Ptaszynska A, Donovan M, Carson P, Massie BM; I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010;16:128-134.
19. Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O'Mahony D, Polonski L, Taylor J. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Fail 1999;1:211-217.
20. Schoenfeld D. Partial residual estimation for the proportional hazards regression. Biometrika 1982;69:239-241.
21. Breslow N. Comparison of survival curves. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer Clinical Trials: Methods and Practice. Oxford: Oxford University Press; 1984. p381-406.
22. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54-77.
23. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
24. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-2216.
25. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC Jr. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47: 874-880.
26. Miller VM, RedfieldMM, McConnell JP. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol 2007;5:15-25.
27. European Study Group on Diastolic Heart Failure. How to diagnose diastolic heart failure. Eur Heart J 1998;19:990-1003.
28. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28: 2539-2550.
29. Cleland JG, Tavazzi L, Daubert J-C, Tageldien A, Freemantle N. Cardiac resynchronization therapy. Are modern myths preventing appropriate use? J Am Coll Cardiol 2009;53:608-611.
30. Berger R, Shankar A, Fruhwald F, Fahrleitner-Pammer A, Freemantle N, Tavazzi L, Cleland JG, Pacher R. Relationships between cardiac resynchronization therapy and NT-BNP in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the CARE-HF trial. Eur Heart J 2009;30:2109-2116.
31. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54:1850-1859.
32. Cleland JG, Squire I, Ng L. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study. J Am Coll Cardiol 2008;52: 1104-1105.